Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control.
Relationship of UV exposure to prevalence of multiple sclerosis in England.
Stressful life-events in childhood and risk of multiple sclerosis: a Danish nationwide cohort study.
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.
Our products
Interleukin-7 expression and its effect on natural killer cells in patients with multiple sclerosis.
Fingolimod effect on brain volume loss independently contributes to its effect on disability.
Vitamin D: Health Panacea or false Prophet?
Detection of differential protein expression in cerebrospinal fluid of patients with multiple sclerosis through two-dimensional differential in gel electrophoresis.
High rates of physician services utilization at least five years before multiple sclerosis diagnosis.
A Combined Inspiratory and Expiratory Muscle Training Program Improves Respiratory Muscle Strength and Fatigue in Multiple Sclerosis.
The common marmoset as a novel animal model system for biomedical and neuroscience research applications.
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Neuromyelitis optica in children: a review of the literature.
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
Erythromelalgia-like presentation of chronic acquired demyelinating polyneuropathy in a setting of past alcohol abuse.
Use of a Time-of-Flight Camera With an Omek Beckon™ Framework to Analyze, Evaluate and Correct in Real Time the Verticality of Multiple Sclerosis Patients during Exercise.
Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis.
Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation.
Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis.
Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure.
Characterisation of uveitis in association with multiple sclerosis.
Oligodendrocyte Precursor Cell-Intrinsic Effect of Rheb1 Controls Differentiation and Mediates mTORC1-Dependent Myelination in Brain.
Morning glory syndrome associated with multiple sclerosis.
Pages
« first
‹ previous
…
248
249
250
251
252
253
254
255
256
…
next ›
last »